Characterization of the pharmacokinetic/pharmacodynamic (PK/PD) profile of a candidate HIV prevention drug in rhesus macaques
Ended Awarded Last action
- Contract number
- 75N93019F00134
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,182,653
Award facts
- Opportunity
-
- NIAIDDAIDSNIHAI2015029 Solicitation number
- Comprehensive Resources for HIV Microbicides and Biomedical Prevention Award Notice · Posted Jun 24, 2015
- Contract value 67% obligated
-
- $2,182,653.00 Current, with exercised options
- $3,273,876.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $89,310 | |
| Other Administrative Action | $0 | |
| Change Order | $968,613 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,124,730 |
About this award
This is a $3,273,876.00 cost-plus-fixed-fee Delivery Order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL) for the characterization of the pharmacokinetic/pharmacodynamic (PK/PD) profile of a candidate HIV prevention drug in rhesus macaques. The contract is part of the Comprehensive Resources for HIV Microbicides and Biomedical Prevention program and has a completion date of December 15, 2024. ABL is a foreign-owned, for-profit manufacturer of goods that specializes in developing biologics, including vaccines and immunotherapies, for government, academic and industry clients. The company has been awarded numerous prime federal contracts and grants, particularly from NIH and HHS, to support infectious disease research and product development.
Quick answers
Who was awarded contract 75N93019F00134?
75N93019F00134 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2019.
How much is contract 75N93019F00134 worth?
The government has obligated $2,182,653 on 75N93019F00134. Its potential value, with all options, is $3,273,876.
Is contract 75N93019F00134 an order under another contract?
Yes. 75N93019F00134 is a delivery order under HHSN272201600008I, an indefinite delivery contract, on HIV Microbicides and Biomedical Prevention 2016-2021.
Was contract 75N93019F00134 competed?
The extent of competition for 75N93019F00134 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award